Malignant mixed mesodermal tumours: Biology and clinical aspects

European Journal of Cancer

Volumn 38, Issue 11, 2002, Pages 1437-1446

  Gourley, C ^a   Al Nafussi, A ^b   Abdulkader, M ^b   Smyth, J F ^a   Gabra, H ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Carcinosarcoma; Mixed malignant mesodermal tumour; Mixed malignant mullerian tumour; Sarcomatoid carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; PACLITAXEL; PLATINUM; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; META ANALYSIS; MIXED MULLERIAN TUMOR; MOLECULAR BIOLOGY; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0036314671     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00114-4     Document Type: Article

References (99)

1. Malignant mixed mullerian tumours of gynaecological origin: Chemosensitive but aggressive tumours
2. Malignant mixed Mullerian tumors of the uterus
3. Mixed mullerian tumors
4. Carcinoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases
5. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients
6. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy
7. Malignant mixed mullerian tumors of the ovary: Experience with surgical cytoreduction and combination chemotherapy
8. Stage I primary malignant mixed mullerian tumor of the fallopian tube. Report of a case with five-year survival after minimal surgery without adjuvant treatment
9. Malignant mixed mullerian tumor of the fallopian tube
10. Malignant mixed Mullerian tumor of the fallopian tube: Report of two cases and review of literature
11. Primary malignant mixed Mullerian tumor of the vagina
12. Malignant mixed mullerian tumor of the extraovarian secondary mullerian system. Report of two cases and review of the English literature
13. Primary malignant mixed Mullerian tumor (metaplastic carcinoma) of the female peritoneum. A clinical, pathologic, and immunohistochemical study of three cases and a review of the literature
14. Primary peritoneal malignant mixed Mullerian tumors. A clinicopathologic, immunohistochemical, and genetic study
15. Carcinosarcoma of the spleen. An extragenital malignant mixed mullerian tumour?
16. Extragenital malignant mixed mullerian tumor
17. Patterns of recurrence in malignant mixed mullerian tumor of the uterus
18. Heterologous mullerian mixed tumor after whole body irradiation because of Hodgkin's disease in stage IV
19. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors
20. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histological types of sarcoma of the uterus
21. Mixed mullerian tumors of the uterus: A clinicopathologic study
22. Malignant Mullerian mixed tumors of the uterus: A study of 21 cases
23. Postirradiation mixed Mullerian tumors of the uterus. A comparative clinicopathological study
24. The endometrium in breast cancer patients on tamoxifen
25. Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: Report on a new case and review of the literature
26. Long-term tamoxifen treatment: A possible aetiological factor in the development of uterine carcinosarcoma two case-reports and review of the literature
27. Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer
28. Mixed mesodermal sarcoma of the ovary
29. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary
30. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri
31. Clinicopathologic analysis of uterine malignant mixed mullerian tumors
32. Management of malignant, mixed mesodermal tumors of the uterus
33. Malignant mixed Mullerian tumors of the uterus
34. Extrauterine pelvic malignant mixed mesodermal tumors. A study of 10 cases with immunohistochemistry
35. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: Report of eight cases and review of literature
36. Histogenesis of ovarian malignant mixed mesodermal tumours
37. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells
38. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: Immunohistochemical and ultrastructural analysis of 28 cases
39. Malignant mixed mullerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations
40. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases
41. Malignant mixed mullerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis
42. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: Comparative molecular analysis of epithelial and mesenchymal components
43. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours
44. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases
45. P53 immunostaining suggests that uterine carcinosarcomas are monoclonal
46. Malignant mixed mullerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation
47. Uterine carcinosarcomas: A clinicopathologic and immunohistochemical study providing evidence that these are biphasic carcinomas
48. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis
49. P53 protein overexpression and gene mutation in mixed Mullerian tumors of the uterus
50. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status
51. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas
52. Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas
53. Loss of H19 imprinting and up-regulation of H19 and SNRPN in a case with malignant mixed Mullerian tumor of the uterus
54. Long-term in vitro growth of a heterologous mixed Mullerian tumor of the ovary
55. Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary
56. Mixed mesodermal tumor of the ovary: Analysis of prognostic factors in 31 cases
57. Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction
58. Malignant mixed mullerian tumors of the ovary: Histopathologic and clinical review of 36 cases
59. Malignant mixed Mullerian tumors of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases
60. Prognostic factors in uterine carcinosarcoma: A clinicopathologic study of 25 patients
61. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus
62. Malignant mixed mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases
63. Homologous mixed Mullerian tumors (carcinosarcoma) confined to endometrial polyps
64. Mesenchymal tumors of the uterus III. A clinical and pathological study of 31 carcinosarcomas
65. Solid teratomas and mixed mullerian tumours of the ovary: A clinical, histological and immunocytochemical comparative study
66. Ovarian sarcoma
67. Malignant mixed Mullerian tumour versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: A comparative analysis of survival
68. The hormonal receptor status of uterine carcinosarcomas (mixed mullerian tumours): An immunohistochemical study
69. Uterine sarcoma: Steroid receptors and response to hormonal therapy
70. Endometrial stromal sarcoma: A clinicopathological study of 11 cases with determination of estrogen and progestin receptor levels in three tumors
71. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma
72. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors
73. Mixed mullerian tumours of the uterine corpus: A review
74. A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A Gynecologic Oncology Group study
75. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy
76. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus
77. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus
78. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma
79. Effects of irradiation on mixed mullerian tumors of the uterus
80. Mixed mullerian tumours of the uterus - Prognostic factors: A clinical and histopathologic study of 147 cases
81. Uterine sarcomas: Analysis of failures with special emphasis on use of adjuvant radiation therapy
82. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri
83. Adjuvant chemotherapy for advanced uterine sarcomas
84. Phase II study of etoposide, adriamycin, cisplatin (EPA) in mixed mullerian tumours of the uterus
85. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group Study
86. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A Gynecologic Oncology Group Study
87. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study)
88. Carcinosarcoma of the ovary treated over a ten year period at the Christie Hospital
89. Paclitaxel in the treatment of carcinosarcoma of the uterus: A gynecologic oncology group study
90. Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy
91. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study
92. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group Study
93. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: A Gynecologic Oncology Group study
94. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study
95. Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy
96. Chemotherapy for malignant mixed Mullerian tumors of the ovary
97. Malignant mixed mesodermal tumour of the peritoneum with a complete response to cyclophosphamide
98. Malignant mixed mullerian tumors of the ovary. An analysis of two long-term survivors
99. Pathologic complete response of advanced ovarian mixed mesodermal tumor to cisplatin, adriamycin and dacarbazine: A case report